Canine pancreatitis injectable lands U.S. distributionMay 18, 2023Panoquell-CA1’s active ingredient, fuzapladib sodium, has been approved for canine use in Japan since 2018.
SPONSORED CONTENTOne dose protects for 12 months.One ProHeart® 12 (moxidectin) injection puts compliance in your control. + Get started
Canine pancreatitis injectable OKed by FDANovember 21, 2022Panoquell-CA1 has been granted conditional approval from the U.S. Food and Drug Administration (FDA) for the management of clinical signs associated with acute onset of pancreatitis in canines.
Clinical trial aims to treat canine pancreatitisFebruary 6, 2020ISK and AlcheraBio are seeking clinics to serve as clinical investigator sites to explore treatment options for patients diagnosed with acute canine pancreatitis (ACP).
